The Effect of Size, Dose, and Administration Route on Zein Nanoparticle Immunogenicity in BALB/c Mice

References

• Paliwal R, Palakurthi S. Zein in controlled drug delivery and tissue engineering. J Control Release. 2014;189:108–122. doi:10.1016/j.jconrel.2014.06.03624993426
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cui L, Che X, et al. Zein-based films and their usage for controlled delivery: origin, classes and current landscape. J Control Release. 2015;206:206–219. doi:10.1016/j.jconrel.2015.03.03025828699
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cui L, Li F, et al. Design, fabrication and biomedical applications of zein-based nano/micro-carrier systems. Int J Pharm. 2016;513(1–2):191–210. doi:10.1016/j.ijpharm.2016.09.02327615709
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cui LL, Chen Y, et al. Zein-based nanofiber for drug delivery: classes and current application. Curr Pharm Des. 2015;21(22):3199–3207. doi:10.2174/138161282166615053117044826027566
   PubMedGoogle Scholar
• Zou T, Gu L. TPGS emulsified zein nanoparticles enhanced oral bioavailability of daidzin: in vitro characteristics and in vivo performance. Mol Pharm. 2013;10(5):2062–2070.23557122
   PubMedGoogle Scholar
• Dong F, Dong X, Zhou L, et al. Doxorubicin-loaded biodegradable self-assembly zein nanoparticle and its anti-cancer effect: preparation, in vitro evaluation, and cellular uptake. Colloids Surf B Biointerfaces. 2016;140:324–331. doi:10.1016/j.colsurfb.2015.12.04826764113
   PubMed Web of Science ®Google Scholar
• Hashem FM, Al-Sawahli MM, Nasr M, Ahmed OA. Optimized zein nanospheres for improved oral bioavailability of atorvastatin. Int J Nanomedicine. 2015;10:4059–4069. doi:10.2147/IJN.S8390626150716
   PubMed Web of Science ®Google Scholar
• Lee S, Alwahab NS, Moazzam ZM. Zein-based oral drug delivery system targeting activated macrophages. Int J Pharm. 2013;454(1):388–393. doi:10.1016/j.ijpharm.2013.07.02623876501
   PubMedGoogle Scholar
• Lai LF, Guo HX. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm. 2011;404(1–2):317–323. doi:10.1016/j.ijpharm.2010.11.02521094232
   PubMedGoogle Scholar
• Berardi A, Bisharat L, AlKhatib HS, Cespi M. Zein as a pharmaceutical excipient in oral solid dosage forms: state of the art and future perspectives. AAPS PharmSciTech. 2018;19(5):2009–2022. doi:10.1208/s12249-018-1035-y29736888
   PubMedGoogle Scholar
• Gong SJ, Sun SX, Sun QS, Wang JY, Liu XM, Liu GY. Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. J Biomater Appl. 2011;26(2):195–208. doi:10.1177/088532821036350420418265
   PubMed Web of Science ®Google Scholar
• Xu H, Shen L, Xu L, Yang Y. Controlled delivery of hollow corn protein nanoparticles via non-toxic crosslinking: in vivo and drug loading study. Biomed Microdevices. 2015;17(1):8. doi:10.1007/s10544-014-9926-525666984
   PubMed Web of Science ®Google Scholar
• Gong S, Wang H, Sun Q, Xue ST, Wang JY. Mechanical properties and in vitro biocompatibility of porous zein scaffolds. Biomaterials. 2006;27(20):3793–3799. doi:10.1016/j.biomaterials.2006.02.01916527348
   PubMedGoogle Scholar
• Wang HJ, Lin ZX, Liu XM, Sheng SY, Wang JY. Heparin-loaded zein microsphere film and hemocompatibility. J Control Release. 2005;105(1–2):120–131. doi:10.1016/j.jconrel.2005.03.01415893840
   PubMed Web of Science ®Google Scholar
• Lin L, Perets A, Har-el YE, et al. Alimentary ‘green’ proteins as electrospun scaffolds for skin regenerative engineering. J Tissue Eng Regen Med. 2013;7(12):994–1008. doi:10.1002/term.149322499248
   PubMedGoogle Scholar
• Lin J, Li C, Zhao Y, Hu J, Zhang LM. Co-electrospun nanofibrous membranes of collagen and zein for wound healing. ACS Appl Mater Interfaces. 2012;4(2):1050–1057. doi:10.1021/am201669z22242622
   PubMed Web of Science ®Google Scholar
• Dong J, Sun Q, Wang JY. Basic study of corn protein, zein, as a biomaterial in tissue engineering, surface morphology and biocompatibility. Biomaterials. 2004;25(19):4691–4697. doi:10.1016/j.biomaterials.2003.10.08415120515
   PubMed Web of Science ®Google Scholar
• Sun QS, Dong J, Lin ZX, Yang B, Wang JY. Comparison of cytocompatibility of zein film with other biomaterials and its degradability in vitro. Biopolymers. 2005;78(5):268–274. doi:10.1002/bip.2029815898117
   PubMedGoogle Scholar
• Wang HJ, Fu JX, Wang JY. Effect of water vapor on the surface characteristics and cell compatibility of zein films. Colloids Surf B Biointerfaces. 2009;69(1):109–115. doi:10.1016/j.colsurfb.2008.11.01519117737
   PubMedGoogle Scholar
• Wang Q, Xian W, Li S, Liu C, Padua GW. Topography and biocompatibility of patterned hydrophobic/hydrophilic zein layers. Acta Biomater. 2008;4(4):844–851. doi:10.1016/j.actbio.2008.01.01718325861
   PubMedGoogle Scholar
• Jiang Q, Reddy N, Yang Y. Cytocompatible cross-linking of electrospun zein fibers for the development of water-stable tissue engineering scaffolds. Acta Biomater. 2010;6(10):4042–4051. doi:10.1016/j.actbio.2010.04.02420438870
   PubMedGoogle Scholar
• Qu ZH, Wang HJ, Tang TT, Zhang XL, Wang JY, Dai KR. Evaluation of the zein/inorganics composite on biocompatibility and osteoblastic differentiation. Acta Biomater. 2008;4(5):1360–1368. doi:10.1016/j.actbio.2008.03.00618439886
   PubMed Web of Science ®Google Scholar
• Luo Y, Teng Z, Wang TT, Wang Q. Cellular uptake and transport of zein nanoparticles: effects of sodium caseinate. J Agric Food Chem. 2013;61(31):7621–7629. doi:10.1021/jf402198r23859760
   PubMed Web of Science ®Google Scholar
• Lin T, Lu C, Zhu L, Lu T. The biodegradation of zein in vitro and in vivo and its application in implants. AAPS PharmSciTech. 2011;12(1):172–176. doi:10.1208/s12249-010-9565-y21184205
   PubMedGoogle Scholar
• Tu J, Wang H, Li H, Dai K, Wang J, Zhang X. The in vivo bone formation by mesenchymal stem cells in zein scaffolds. Biomaterials. 2009;30(26):4369–4376. doi:10.1016/j.biomaterials.2009.04.05419539987
   PubMedGoogle Scholar
• Wang HJ, Gong SJ, Lin ZX, et al. In vivo biocompatibility and mechanical properties of porous zein scaffolds. Biomaterials. 2007;28(27):3952–3964. doi:10.1016/j.biomaterials.2007.05.01717582490
   PubMed Web of Science ®Google Scholar
• Hurtado-Lopez P, Murdan S. An investigation into the adjuvanticity and immunogenicity of zein microspheres being researched as drug and vaccine carriers. J Pharm Pharmacol. 2006;58(6):769–774. doi:10.1211/jpp.58.6.000716734978
   PubMed Web of Science ®Google Scholar
• Perumal OP, Podaralla SK, Kaushik RS, Inventors; South Dakota State University, assignee. Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor. 2009.
   Google Scholar
• Johnson RB, Labrooy JT, Skerritt JH. Antibody responses reveal differences in oral tolerance to wheat and maize grain protein fractions. Clin Exp Immunol. 1990;79(1):135–140. doi:10.1111/j.1365-2249.1990.tb05140.x2302832
   PubMedGoogle Scholar
• Pasini G, Simonato B, Curioni A, et al. IgE-mediated allergy to corn: a 50 kDa protein, belonging to the reduced soluble proteins, is a major allergen. Allergy. 2002;57(2):98–106. doi:10.1034/j.1398-9995.2002.1o3413.x11929411
   PubMedGoogle Scholar
• Lee S-H, Benmoussa M, Sathe SK, Roux KH, Teuber SS, Hamaker BR. A 50 kDa maize γ-zein has marked cross-reactivity with the almond major protein. J Agric Food Chem. 2005;53(20):7965–7970. doi:10.1021/jf047961816190657
   PubMedGoogle Scholar
• Cabrera-Chavez F, Rouzaud-Sandez O, Sotelo-Cruz N, Calderon de la Barca AM. Bovine milk caseins and transglutaminase-treated cereal prolamins are differentially recognized by IgA of celiac disease patients according to their age. J Agric Food Chem. 2009;57(9):3754–3759. doi:10.1021/jf802596g19290628
   PubMedGoogle Scholar
• Krishnan HB, Jang S, Kim WS, Kerley MS, Oliver MJ, Trick HN. Biofortification of soybean meal: immunological properties of the 27 kDa gamma-zein. J Agric Food Chem. 2011;59(4):1223–1228. doi:10.1021/jf103613s21226519
   PubMedGoogle Scholar
• Li F, Chen Y, Liu SB, et al. Size-controlled fabrication of zein nano/microparticles by modified anti-solvent precipitation with/without sodium caseinate. Int J Nanomedicine. 2017;12:8197–8209.29184408
   PubMed Web of Science ®Google Scholar
• Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008;2008:pdb prot4986. doi:10.1101/pdb.prot493921356829
   PubMedGoogle Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi:10.1146/annurev.iy.07.040189.0010452523712
   PubMed Web of Science ®Google Scholar
• Vega-Ramos J, Roquilly A, Asehnoune K, Villadangos JA. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Curr Opin Pharmacol. 2014;17:64–70. doi:10.1016/j.coph.2014.07.01325128781
   PubMed Web of Science ®Google Scholar
• Benne N, van Duijn J, Kuiper J, Jiskoot W, Slutter B. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines. J Control Release. 2016;234:124–134. doi:10.1016/j.jconrel.2016.05.03327221070
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404–1413. doi:10.1002/(ISSN)1521-414118389478
   PubMed Web of Science ®Google Scholar
• Li X, Sloat BR, Yanasarn N, Cui Z. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm. 2011;78(1):107–116. doi:10.1016/j.ejpb.2010.12.01721182941
   PubMed Web of Science ®Google Scholar
• Vlkova M, Rohousova I, Hostomska J, et al. Kinetics of antibody response in BALB/c and C57BL/6 mice bitten by Phlebotomus papatasi. PLoS Negl Trop Dis. 2012;6(7):e1719. doi:10.1371/journal.pntd.000171922802977
   PubMedGoogle Scholar
• Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710–724. doi:10.1080/14686996.2019.162717431275462
   PubMed Web of Science ®Google Scholar
• Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112(1):15–25. doi:10.1016/j.jconrel.2006.01.00516515818
   PubMed Web of Science ®Google Scholar
• Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther. 2005;312(3):1020–1026. doi:10.1124/jpet.104.07811315525796
   PubMed Web of Science ®Google Scholar
• Wang F, Ye X, Wu Y, et al. Time interval of two injections and first-dose dependent of accelerated blood clearance phenomenon induced by PEGylated liposomal gambogenic acid: the contribution of PEG-specific IgM. J Pharm Sci. 2019;108(1):641–651. doi:10.1016/j.xphs.2018.10.02730595169
   PubMed Web of Science ®Google Scholar
• Li C, Zhao X, Wang Y, et al. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan. Int J Pharm. 2013;443(1–2):17–25. doi:10.1016/j.ijpharm.2013.01.01223318366
   PubMed Web of Science ®Google Scholar